263 products were found matching "K05099"!

Description: HGFR/c-Met Protein, Human, Recombinant (His), AF488-Labeled is expressed in HEK293 Cells. The accession number is P08581-1.

JNJ-26483327 is an inhibitor of Met. It also inhibits EGFR, HER2, and HER4 (IC50s = 9.6, 18, and 40.3 nM, respectively). JNJ-26483327 (5 or 10 µM), in combination with trastuzumab, reduces HER2 phosphorylation in BT474 breast cancer cells. It decreases tumor volume when used in combination with trastuzumab in a...

Protein function: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces...

INCB 28060 is an inhibitor of heptatocyte growth factor receptor (HGFR, also known as c-Met), potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM). It blocks cell proliferation and migration or induces apoptosis...

The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor, have been implicated in the development and progression of several human cancers. PHA-665752 is an ATP-competitive, active-site inhibitor of the catalytic activity of c-Met kinase (Ki = 4 nM, IC50 = 9 nM). It exhibits >50-fold selectivity...

Foretinib is a broad-spectrum tyrosine kinase (TK) inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRbeta, and Tie-2, at nanomolar concentrations. It blocks HGF-induced Met phosphorylation and VEGF-induced ERK phosphorylation, preventing HGF-induced responses in...

(R)-Crizotinib is a dual inhibitor of c-Met and anaplastic lymphoma kinase (ALK, IC50s = 8 and 20 nM, respectively, in a cell-based assay). It is selective for c-Met and ALK over several other receptor- and non-receptor tyrosine kinases, including Ron, Tie2, Abl, LCK, and VEGFR2 (IC50s = 0.08, 0.448, 1.159, 2.741,...

AMG 337 is an orally active and selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways. It has been shown to inhibit hepatocyte growth factor-mediated c-Met phosphorylation in PC3 cells (IC50 = 5 nM) and to...

The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer. SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM. It is over 1,000-fold selective for c-Met over a panel of other kinases....

NPS 1034 is a dual inhibitor of the receptor tyrosine kinase activities of MET (IC50 = 48 nM) and AXL (IC50 = 10.3 nM), receptors for hepatocyte growth factor and vitamin K-dependent proteins, respectively. It synergistically inhibits cell proliferation when used in combination with gefitinib (Cay-13166) or...

Glumetinib is a potent inhibitor of c-Met (IC50 = 0.42 nM). It is greater than 2,400-fold selective for c-Met over a panel of 312 kinases. Glumetinib (0.001-1 µM) inhibits c-Met phosphorylation in and proliferation of MET-overexpressing EBC-1 lung and MKN45 gastric cancer cells. It inhibits NCI H441 cell motility...

Altiratinib is a multiple kinase inhibitor, blocking Met, Tie2, VEGF2, TrkA, TrkB, and TrkC with IC50 values of 2.7, 8.0, 9.2, 0.85, 4.6, and 0.83 nM, respectively. It also inhibits several mutant Met isoforms at nanomolar concentrations. Altiratinib inhibits the proliferation of several cancer cell lines in vitro...